Journal of Immunology Research / 2015 / Article / Tab 1

Research Article

A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells

Table 1

Binding affinity and ribonucleolytic activity of SPDP-based ADCs.

OARBinding affinityRibonucleolytic activity
(nM)/ (103 M−1s−1)

ONCNA14.1 ± 0.8
huRFB4 IgG0.27 ± 0.02NA
SPDP-based 162 kDa ADC 1 : 10.39 ± 0.0314.1 ± 0.8
SPDP-based 174 kDa ADC 2 : 10.47 ± 0.0326.5 ± 2.4
SPDP-based 186 kDa ADC 3 : 10.62 ± 0.0340.2 ± 3.3

Relative binding affinity () to CD22-positive Raji cells was calculated from equilibrium-binding curves as determined by flow cytometry performed in triplicate. Ribonucleolytic activity (/) was determined from at least three independent assays. Values are expressed as mean ± SE.
NA: not applicable.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.